CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 54 enrolled
Drug / intervention
Fludarabine monophosphate, melphalan, Bortezomibdrug
Likely dose
Fludarabine monophosphate, melphalan, Bortezomib 140 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01453101
NCT01453101Phase 2Completed
CompareCT.gov

A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma Using a Conditioning Regimen of Fludarabine, Melphalan, and Bortezomib

Hackensack Meridian Health·interventional·Posted Oct 17, 2011·Updated Apr 8, 2026

In Brief

A Phase 2 clinical trial evaluating Fludarabine monophosphate, melphalan, Bortezomib for Multiple Myeloma. Completed, enrolled 54 participants across 1 site.

Detailed Summary

The hypothesis for this study is that the regimen consisting of fludarabine, melphalan and bortezomib improves the progression free survival and the response rate compared to historical controls of fludarabine and melphalan alone.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 17, 2011
Enrollment StartJun 9, 2010
Primary CompletionJun 11, 2020
TodayJul 2, 2026
Enrollment to primary: 10.0 yearsPosted 14.7 years ago

Interventions

Fludarabine monophosphate, melphalan, Bortezomibdrug

* Fludarabine will be administered at a dose of 30/mg/m2 IV daily for 4 days starting on transplant day -5. * Melphalan will be administered at a dose of 140 mg/m2 on transplant day-2 * Bortezomib will be administered by rapid IV push at a dose of 1.6mg/m2 on days-4 and -1. The bortezomib should be given at least 20 hours after the melphalan.